Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease

Neuroscience

Volumn 298, Issue , 2015, Pages 389-396

  Fidalgo, C ^a   Ko, W K D ^b,c   Tronci, E ^a   Li, Q ^c,d   Stancampiano, R ^a   Chuan, Q ^d   Bezard, E ^b,c,d   Carta, M ^a  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

^c Williams House   (United Kingdom)

^d INSTITUTE OF LABORATORY ANIMAL SCIENCE   (China)

Author keywords

Citalopram; Dopamine; Dyskinesia; Parkinson's disease; Serotonin

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CITALOPRAM; ELTOPRAZINE; SEROTONIN TRANSPORTER; ANTIPARKINSON AGENT; LEVODOPA; OXIDOPAMINE; SEROTONIN UPTAKE INHIBITOR; TYROSINE 3 MONOOXYGENASE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; LEVODOPA-INDUCED DYSKINESIA; MACAQUE MODEL; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; TIME TO TREATMENT; ANALYSIS OF VARIANCE; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; DYSKINESIA, DRUG-INDUCED; MACACA FASCICULARIS; METABOLISM; MPTP POISONING; SPRAGUE DAWLEY RAT; TIME;

ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; CITALOPRAM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; MALE; MPTP POISONING; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 84929660329     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2015.04.027     Document Type: Article

References (60)

1. Ahlskog J.E., Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001, 16(3):448-458.
2. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., Crossman A.R., Bioulac B., Brotchie J.M., Gross C.E. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2001, 21(17):6853-6861.
3. Bezard E., Ferry S., Machm U., Stark H., Leriche L., Boraud T., Gross C., Sokoloff P. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. Nat Med 2003, 9:762-767.
4. Bezard E., Muñoz A., Tronci E., Pioli E.Y., Li Q., Porras G., Björklund A., Carta M. Anti-dyskinetic effect of anpirtoline in animal models of L-DOPA-induced dyskinesia. Neurosci Res 2013, 77(4):242-246.
5. Bezard E., Tronci E., Pioli E.Y., Li Q., Porras G., Björklund A., Carta M. Study of the anti-dyskinetic effect of eltoprazine in animal models of levodopa-induced dyskinesia. Mov Disord 2013, 28(8):1088-1096.
6. Bishop C., Georgem J.A., Buchta W., Goldenberg A.A., Mohamed M., Dickinson S.O., Eissa S., Eskow Jaunarajs K.L. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats. Eur J Neurosci 2012, 36(6):2839-2848.
7. Blier P., Ward N.M. Is there a role for 5-HT1A agonists in the treatment of depression?. Biol Psychiatry 2003, 53(3):193-203.
8. Carta M., Tronci E. Serotonin system implication in l-DOPA-induced dyskinesia: from animal models to clinical investigations. Front Neurol 2014, 20(5):78.
9. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain 2007, 130:1819-1833.
10. Carta M., Carlsson T., Muñoz A., Kirik D., Björklund A. Involvement of the serotonin system in L-dopa-induced dyskinesias. Parkinsonism Relat Disord 2008, 14(Suppl 2):S154-S158.
11. Chotibut T., Fields V., Salvatore M.F. Norepinephrine transporter inhibition with desipramine exacerbates L-DOPA-induced dyskinesia: role for synaptic dopamine regulation in denervated nigrostriatal terminals. Mol Pharmacol 2014, 86(6):675-685.
12. Chung K.A., Carlson N.E., Nutt J.G. Short-term paroxetine treatment does not alter the motor response to levodopa in PD. Neurology 2005, 64(10):1797-1798.
13. Conti M.M., Ostock C.Y., Lindenbach D., Goldenberg A.A., Kampton E., Dell'isola R., Katzman A.C., Bishop C. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats. Neuropharmacology 2014, 77:1-8.
14. Darling R.D., Alzghoul L., Zhang J., Khatri N., Paul I.A., Simpson K.L., Lin R.C. Perinatal citalopram exposure selectively increases locus ceruleus circuit function in male rats. J Neurosci 2011, 31(46):16709-16715.
15. de la Fuente-Fernández R., Sossi V., Huang Z., Furtado S., Lu J.Q., Calne D.B., Ruth T.J., Stoessl A.J. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004, 127:2747-2754.
16. Dell'Agnello G., Ceravolo R., Nuti A., Bellini G., Piccinni A., D'Avino C., Dell'Osso L., Bonuccelli U. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001, 24(4):221-227.
17. Devos D., Dujardin K., Poirot I., Moreau C., Cottencin O., Thomas P., Destée A., Bordet R., Defebvre L. Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008, 23(6):850-857.
18. Durif F., Vidailhet M., Bonnet A.M., Blin J., Agid Y. Levodopa-induced dyskinesias are improved by fluoxetine. Neurology 1995, 45:1855-1858.
19. El Mansari M., Sánchez C., Chouvet G., Renaud B., Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an in vivo electrophysiological study in rat brain. Neuropsychopharmacology 2005, 30(7):1269-1277.
20. Eskow K.L., Dupre K.B., Barnum C.J., Dickinson S.O., Park J.Y., Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009, 63(7):610-620.
21. Fox S.H., Johnston T.H., Li Q., Brotchie J., Bezard E. A critique of available scales and presentation of the non-human primate dyskinesia rating scale. Mov Disord 2012, 27:1373-1378.
22. Fulceri F., Biagioni F., Ferrucci M., Lazzeri G., Bartalucci A., Galli V., Ruggieri S., Paparelli A., Fornai F. Abnormal involuntary movements (AIMs) following pulsatile dopaminergic stimulation: severe deterioration and morphological correlates following the loss of locus coeruleus neurons. Brain Res 2007, 1135(1):219-229.
23. Goodwin G.M. How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 1996, 57(4):9-13.
24. Guigoni C., Dovero S., Aubert I., Li Q., Bioulac B.H., Bloch B., Gurevich E.V., Gross C.E., Bezard E. Levodopa-induced dyskinesia in MPTP-treated macaque is not dependent of the extent and pattern of the nigrostrial lesion. Eur J Neurosci 2005, 22:283-287.
25. Hansard M.J., Smith L.A., Jackson M.J., Cheetham S.C., Jenner P. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther 2002, 303(3):952-958.
26. Huot P., Johnston T.H., Lewis K.D., Koprich J.B., Reyes M.G., Fox S.H., Piggott M.J., Brotchie J.M. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. J Neurosci 2011, 31(19):7190-7198.
27. Huot P., Johnston T.H., Lewis K.D., Koprich J.B., Reyes M.G., Fox S.H., Piggott M.J., Brotchie J.M. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology 2014, 82:76-87.
28. Huston J.P., van den Brink J., Komorowski M., Huq Y., Topic B. Antidepressants reduce extinction-induced withdrawal and biting behaviors: a model for depressive-like behavior. Neuroscience 2012, 17(210):249-257.
29. Iravani M.M., Jackson M.J., Kuoppamäki M., Smith L.A., Jenner P. 3,4-methylenedioxymethamphetamine (ecstasy) inhibits dyskinesia expression and normalizes motor activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Neurosci 2003, 23(27):9107-9115.
30. Kawahara Y., Kawahara H., Kaneko F., Tanaka M. Long-term administration of citalopram reduces basal and stress-induced extracellular noradrenaline levels in rat brain. Psychopharmacology 2007, 194(1):73-81.
31. Ko W.K., Pioli E., Li Q., McGuire S., Dufour A., Sherer T.B., Bezard E., Facheris M.F. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. Mov Disord 2014, 29(6):772-779.
32. Komorowski M., Huston J.P., Klingenhegel I., Paulat J., Sackers J., Topic B. Distance from source of reward as a marker for extinction-induced "despair": modulation by the antidepressants clomipramine and citalopram. Neuroscience 2012, 25(223):152-162.
33. Korsgaard S., Noring U., Povlsen U.J., Gerlach J. Effects of citalopram, a specific serotonin uptake inhibitor, in tardive dyskinesia and parkinsonism. Clin Neuropharmacol 1986, 9(1):52-57.
34. Kuan W.L., Zhao J.W., Barker R.A. The role of anxiety in the development of levodopa-induced dyskinesias in an animal model of Parkinson's disease, and the effect of chronic treatment with the selective serotonin reuptake inhibitor citalopram. Psychopharmacology 2008, 197:279-293.
35. Kugelberg F.C., Apelqvist G., Bengtsson F. Effects of chronic citalopram treatment on central and peripheral spontaneous open-field behaviours in rats. Pharmacol Toxicol 2002, 90(6):303-310.
36. Lima F.B., Centeno M.L., Costa M.E., Reddy A.P., Cameron J.L., Bethea C.L. Stress sensitive female macaques have decreased fifth Ewing variant (Fev) and serotonin-related gene expression that is not reversed by citalopram. Neuroscience 2009, 164(2):676-691.
37. Linazasoro G. Worsening of Parkinson's disease by citalopram. Parkinsonism Relat Disord 2000, 6(2):111-113.
38. Loane C., Politis M. Buspirone: what is it all about?. Brain Res 2012, 21(1461):111-118.
39. Lundblad M., Andersson M., Winkler C., Kirik D., Wierup N., Cenci M.A. Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease. Eur J Neurosci 2002, 15(1):120-132.
40. Mazzucchi S., Frosini D., Ripoli A., Nicoletti V., Linsalata G., Bonuccelli U., Ceravolo R. Serotonergic antidepressant drugs and L-dopa-induced dyskinesias in Parkinson's disease. Acta Neurol Scand 2015, 131(3):191-195.
41. Menza M., Marin H., Kaufman K., Mark M., Lauritano M. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004, 16(3):315-319.
42. Menza M., Dobkin R.D., Marin H., Mark M.H., Gara M., Buyske S., Bienfait K., Dicke A. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009, 72(10):886-892.
43. Miletić V., Relja M. Citalopram-induced parkinsonian syndrome: case report. Clin Neuropharmacol 2011, 34(2):92-93.
44. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., Kirik D., Di Luca M., Björklund A., Bezard E., Carta M. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131(12):3380-3394.
45. Navailles S., Bioulac B., Gross C., De Deurwaerdère P. Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiol Dis 2010, 38(1):136-143.
46. Nevalainen N., Af Bjerkén S., Gerhardt G.A., Strömberg I. Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia. Neuroscience 2014, 28(260):73-86.
47. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1998, Academic Press, San Diego.
48. Politis M., Wu K., Loane C., Brooks D.J., Kiferle L., Turkheimer F.E., Bain P., Molloy S., Piccini P. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients. J Clin Invest 2014, 124(3):1340-1349.
49. Rampello L., Chiechio S., Raffaele R., Vecchio I., Nicoletti F. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol 2002, 25(1):21-24.
50. Schreiber G., Avissar S. Regulators of G-protein-coupled receptor-G-protein coupling: antidepressants mechanism of action. Expert Rev Neurother 2007, 7(1):75-84.
51. Shin E., Rogers J.T., Devoto P., Björklund A., Carta M. Noradrenaline neuron degeneration contributes to motor impairments and development of L-DOPA induced dyskinesia in a rat model of Parkinson's disease. Exp Neurol 2014, 257:25-38.
52. Szabo S.T., de Montigny C., Blier P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int J Neuropsychopharmacol 2000, 3(1):1-11.
53. Tanaka H., Kannari K., Maeda T., Tomiyama M., Suda T., Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999, 10(3):631-634.
54. Tronci E., Carta M. 5-HT1 receptor agonists for the treatment of L-DOPA-induced dyskinesia: from animal models to clinical investigation. Basal Ganglia 2013, 3(1):9-13.
55. Tronci E., Shin E., Björklund A., Carta M. Amphetamine-induced rotation and L-DOPA-induced dyskinesia in the rat 6-OHDA model: a correlation study. Neurosci Res 2012, 73(2):168-172.
56. Tronci E., Lisci C., Stancampiano R., Fidalgo C., Collu M., Devoto P., Carta M. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model. Neurobiol Dis 2013, 60:108-114.
57. Tronci E., Fidalgo C., Zianni E., Collu M., Stancampiano R., Morelli M., Gardoni F., Carta M. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease. Neuroscience 2014, 265:245-252.
58. Weissheimer K.V., Herod S.M., Cameron J.L., Bethea C.L. Interactions of corticotropin-releasing factor, urocortin and citalopram in a primate model of stress-induced amenorrhea. Neuroendocrinology 2010, 92(4):224-234.
59. Winter C., von Rumohr A., Mundt A., Petrus D., Klein J., Lee T., Morgenstern R., Kupsch A., Juckel G. Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats. Behav Brain Res 2007, 184(2):133-141.
60. Zhang J., Darling R.D., Paul I.A., Simpson K.L., Chen K., Shih J.C., Lin R.C. Altered expression of tyrosine hydroxylase in the locus coeruleus noradrenergic system in citalopram neonatally exposed rats and monoamine oxidase a knock out mice. Anat Rec 2011, 294(10):1685-1697.